ProPhase Labs, Inc. Interest Expense Nonoperating
ProPhase Labs, Inc. (PRPH) reported Interest Expense Nonoperating of $791.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-19
- ProPhase Labs, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $791.00K, a 34.75% increase year-over-year.
- ProPhase Labs, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $651.00K, a 20.78% increase year-over-year.
- ProPhase Labs, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $4.26M, a 205.45% increase year-over-year.
- ProPhase Labs, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $1.55M, a 55.99% increase year-over-year.
- ProPhase Labs, Inc. interest expense nonoperating for fiscal 2025 was $6.93M, a 106.96% increase from fiscal 2024.
- ProPhase Labs, Inc. interest expense nonoperating for fiscal 2024 was $3.35M, a 164.61% increase from fiscal 2023.
- ProPhase Labs, Inc. interest expense nonoperating for fiscal 2023 was $1.27M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 3 month as first filed | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 6 month as first filed | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 9 month as first filed | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $791.00K 10-Q · filed 2026-08-19 | $1.44M 10-Q · filed 2026-08-19 | $5.70M derived: sum of 3 quarters · filed 2026-08-19 | $7.25M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2026-03-31 | $651.00K 10-Q/A · filed 2026-07-09 | $4.91M derived: sum of 2 quarters · filed 2026-07-09 | $6.46M derived: sum of 3 quarters · filed 2026-07-09 | $7.04M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $5.81M derived: sum of 2 quarters · filed 2026-06-01 | $6.39M derived: sum of 3 quarters · filed 2026-08-19 | $6.93M 10-K · filed 2026-06-01 | |||
| 2025-09-30 | $1.55M 10-Q · filed 2025-11-19 | $2.14M derived: sum of 2 quarters · filed 2026-08-19 | $2.67M 10-Q · filed 2025-11-19 | $4.07M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-06-30 | $587.00K 10-Q · filed 2026-08-19 | $1.13M 10-Q · filed 2026-08-19 | $2.52M derived: sum of 3 quarters · filed 2026-08-19 | $3.51M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2025-03-31 | $539.00K 10-Q/A · filed 2026-07-09 | $1.93M derived: sum of 2 quarters · filed 2026-07-09 | $2.93M derived: sum of 3 quarters · filed 2026-07-09 | $3.45M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $2.39M derived: sum of 2 quarters · filed 2026-06-01 | $2.91M derived: sum of 3 quarters · filed 2026-06-01 | $3.35M 10-K · filed 2026-06-01 | |||
| 2024-09-30 | $993.00K 10-Q · filed 2025-11-19 | $1.16M 10-Q · filed 2024-11-13 | $1.51M derived: sum of 2 quarters · filed 2025-11-19 | $1.96M 10-Q · filed 2025-11-19 | $2.32M 10-Q · filed 2024-11-13 | $2.44M derived: sum of 4 quarters · filed 2025-11-19 | |
| 2024-06-30 | $522.00K 10-Q · filed 2025-08-13 | $643.00K 10-Q · filed 2024-08-14 | $963.00K 10-Q · filed 2025-08-13 | $1.16M 10-Q · filed 2024-08-14 | $1.45M derived: sum of 3 quarters · filed 2025-08-13 | $1.72M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $441.00K 10-Q · filed 2025-05-20 | $926.00K derived: sum of 2 quarters · filed 2025-05-20 | $1.20M derived: sum of 3 quarters · filed 2025-05-20 | $1.49M derived: sum of 4 quarters · filed 2025-05-20 | |||
| 2023-12-31 | $485.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $760.00K derived: sum of 2 quarters · filed 2025-04-01 | $1.05M derived: sum of 3 quarters · filed 2025-04-01 | $1.27M 10-K · filed 2025-04-01 | |||
| 2023-09-30 | $275.00K 10-Q · filed 2024-11-13 | $566.00K derived: sum of 2 quarters · filed 2024-11-13 | $781.00K 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | $291.00K 10-Q · filed 2024-08-14 | $506.00K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |